EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.3 · March 2024 Financing
March 2024 Financing
| Estimated Amountto be Expended | Estimated Amount tobe Expended (1) | Actual Amount Expended | |
|---|---|---|---|
| CDN$ | US$ | US$ | |
| Research and development activities for EP-104GI and EP-104IAR | 12,100,000 | 8,941,107 | 7,485,149 |
| General and administrative expenses | 7,700,000 | 5,689,795 | 6,951,735 |
| Amended and restated license agreement payment | 6,700,000 | 5,000,000 | 5,000,000 |
| Total | 26,500,000 | 19,630,902 | 19,436,884 |
| (1) | Converted as of March 15, 2024, using the daily rate of exchange published by the Bank of Canada of US$1.00 = CDN$1.3533 with the exception of the license payment which is denominated in the Company’s reporting currency. |
We intend to use a portion of the capital resources previously identified for EP-104IAR development to continue development of EP-104GI.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.